TBCRC 019: An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC or Abraxane®) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with metastatic triple negative breast cancer

PURPOSE: Tigatuzumab (TIG), an agonistic anti-DR5 monoclonal antibody, triggers apoptosis in DR5+ human tumor cells without crosslinking. TIG has strong in vitro/in vivo activity against basal-like breast cancer cells enhanced by chemotherapy agents. This study evaluates activity of TIG and chemothe...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Forero-Torres, Andres, Varley, Katherine E., Abramson, Vandana Gupta, Li, Yufeng, Vaklavas, Christos, Lin, Nancy U., Liu, Minetta C., Rugo, Hope S., Nanda, Rita, Storniolo, Anna Maria, Traina, Tiffany A., Patil, Sujata, Van Poznak, Catherine H., Nangia, Julie R., Irvin, William Johnson, Krontiras, Helen, De Los Santos, Jennifer F., Haluska, Paul, Grizzle, William, Meyers, Richard M., Wolff, Antonio C.
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6186432/
https://ncbi.nlm.nih.gov/pubmed/25779953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2780
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires